Duration of action of abobotulinumtoxinA and onabotulinumtoxinA: A randomized, double-blind study using a contralateral frontalis model

Journal of Clinical and Aesthetic Dermatology

Volumn 4, Issue 9, 2011, Pages 43-49

  Nestor, Mark S ^a,b   Ablon, Glynis R ^c,d  

^a Center for Clinical and Cosmetic Research   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c Skin Institute   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; FRONTALIS LINE; FRONTALIS RATING SCALE; HUMAN; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SKIN BRUISING; SKIN DEFECT; TREATMENT DURATION;

EID: 80755141437     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Carruthers J, Lowe N, Menter M, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46:840-849.
2. Carruthers J, Lowe N, Menter M, et al. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg. 2003;112:1089-1098. (Pubitemid 38251807)
3. Ascher B, Zakine B, Kestemont P, et al. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol. 2004;51:223-233.
4. Monheit G, Carruthers A, Brandt F, Rand R. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg. 2007;33(Suppl):S51-S59. (Pubitemid 46051400)
5. Brandt F, Swanson N, Baumann L, Huber B. Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatol Surg. 2009;35:1893-1901.
6. Dysport™ for Injection [package insert]. Scottsdale, AZ: Medicis Aesthetics Inc.; 2009.
7. Botox® Cosmetic for Injection [package insert]. Irvine, CA: Allergan Inc.; 2009.
8. Lietzow M, Gielow E, Le D, Zhang J, Verhagen M. Subunit stoichiometry of the Clostridium botulinum type A neurotoxin complex determined using denaturing capillary electrophoresis. Protein J. 2008;27:420-425.
9. Panjwani N, O'Keeffe R, Pickett A. Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use. Botulinum J. 2008;1:153-166.
10. Wenzel R, Jones D, Borrego J. Comparing two botulinum toxin type A formulations using manufacturers' product summaries. J Clin Pharm Ther. 2007;32:387-402. (Pubitemid 47063164)
11. Lowe P, Patnaik R, Lowe N. A comparison of two botulinum type A toxin preparations for the treatment of glabellar lines: double-blind, randomized, pilot study. Dermatol Surg. 2005;31: 1651-1654. (Pubitemid 43031167)
12. Hexsel D, Dal'forno T, Hexsel Y, et al. A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A. Dermatol Surg. 2007;34:52-59.
13. Rystedt A, Swartling C, Färnstrand C, Naver H. Equipotent concentrations of Botox and Dysport in the treatment of palmar hyperhidrosis. Acta Derm Venereol. 2008;88:458-461.
14. Karsai S, Adrian R, Hammes S, et al. A randomized double-blind study of the effect of Botox and Dysport/Reloxin on forehead wrinkles and electromyographic activity. Arch Dermatol. 2007;143:1447-1449. (Pubitemid 350146281)
15. Wohlfarth K, Schwandt I, Wegner F, et al. Biological activity of two botulinum toxin type A complexes (Dysport and Botox) in volunteers: a double-blind, randomized, dose-ranging study. J Neurol. 2008;255:1932-1939.
16. Trindade de Almeida A, De Boulle K. Diffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applications. J Cosmet Laser Ther. 2007;9(Suppl 1):17-22. (Pubitemid 47450877)
17. Rosales R, Bigalke H, Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol. 2006;13(Suppl 1):2-10.
18. Karsai S, Raulin C. Current evidence on the unit equivalence of different botulinum neurotoxin A formulations and recommendations for clinical practice in dermatology. Dermatol Surg. 2009;35:1-8.
19. Klein A, Carruthers A, Fagien S, Lowe N. Comparisons among botulinum toxins: an evidence-based review. Plast Reconstr Surg. 2008;121:413-422e.
20. Hexsel D, Rutowitsch M, DE Castro L, al e. Blind multicenter study of the efficacy and safety of injections of a commercial preparation of botulinum toxin type A reconstituted up to 15 days before injection. Dermatol Surg. 2009;35:933-940.
21. Wohlfarth K, Sycha T, Ranoux D, Naver H, Caird D. Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment? Curr Med Res Opin. 2009;25:1573-1584.
22. Lowe P, Patnaik R, Lowe N. Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. J Am Acad Dermatol. 2006;55: 975-980. (Pubitemid 44716484)
23. Lowe N, Shah A, Lowe P, Patnaik R. Dosing, efficacy and safety plus the use of computerized photography for botulinum toxins type A for upper facial lines. J Cosmet Laser Ther. 2010;12:106-111.
24. Nettar KD, Yu KC, Bapna S, Boscardin J, Maas CS. An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Arch Facial Plast Surg. 2011 Jun 20 [Epub ahead of print].
25. Nestor M, Ablon G. The Frontalis Activity Measurement Standard: a novel contralateral method for assessing botulinum neurotoxin type-A activity. J Drugs Dermatol. 2011;10(9);968-972.
26. Carruthers A, Carruthers J, Hardas B, et al. A validated grading scale for forehead lines. Dermatol Surg. 2008;34(Suppl 2): S155-S160.
27. Nestor M, Ablon G. Comparing the clinical attributes of abobotulinumtoxinA and onabotulinumtoxinA utilizing a novel contralateral frontalis model and the Frontalis Activity Measurement Standard. J Drugs Dermatol. 2011;10(10). In press.
28. Carruthers A, Carruthers J. A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. J Drugs Dermatol. 2009;8:924-929.
29. Flynn T. Botulinum toxin: examining duration of effect in facial aesthetic applications. Am J Clin Dermatol. 2010;11:183-199.
30. Prager W, Wissmüller E, Kollhorst B, Williams S, Zschocke I. Comparison of two botulinum toxin type A preparations for treating crow's feet: a split-face, double-blind, proof-of-concept study. Dermatol Surg. 2010;36(Suppl 4):2155-2160.